# FDA 483 - Damien Sanderlin, MD - March 29, 2012

Source: https://www.keypedia.com/records/483/damien-sanderlin-md/08ccd4e9-1c38-4111-b0e7-e518f24d7e0c

> FDA 483 for Damien Sanderlin, MD on March 29, 2012. Product: other. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Damien Sanderlin, MD
- Inspection Date: 2012-03-29
- Product Type: other
- Office Name: Dallas District Office
- Summary: An FDA inspection of Damien Sanderlin, MD in Houston, TX, revealed a significant issue with informed consent during a clinical trial for the OraQuick ADVANCE HIV 1/2 Antibody Test. The firm failed to obtain proper informed consent from human subjects prior to initiating blood draws, with multiple instances observed where consent forms were signed after samples were collected. This indicates a serious deviation from regulations regarding the protection of human subjects.

## Related Officers

- [Acting Program Division Director ](https://www.keypedia.com/people/charles-d-brown/8b817b44-437e-476c-b2b2-1c4c6e7e7b54)

Company: https://www.keypedia.com/companies/damien-sanderlin-md/ee882a7a-e0f5-4507-a51a-8796cab9d12f

Office: https://www.keypedia.com/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9